Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

FDA PMA

Lymph node location system during sentinel biopsy procedure

PMA Number: P160053 · 2026-05-18

Decision Date2026-05-18
PMA NumberP160053
Product CodePUV
Device ClassClass 3
Medical SpecialtyU
Advisory CommitteeSU

Device Summary

Lymph node location system during sentinel biopsy procedure is the device name listed in this FDA PMA record. The listed applicant is Endomagnetics Ltd.,. It received FDA Premarket Approval (PMA) on 2026-05-18 under PMA number P160053. The device is classified under FDA product code PUV. It was reviewed by the SU advisory panel. This device is classified as Class III by the FDA. Class III devices subject to the most stringent regulatory controls. These devices generally require premarket approval (PMA) because they support or sustain human life, are of substantial importance in preventing impairment of human health, or present a potential unreasonable risk of illness or injury. PMA is the most stringent type of device marketing application required by the FDA. The device falls under the medical specialty of U. Unlike 510(k) clearance, which demonstrates substantial equivalence to a predicate device, PMA requires valid scientific evidence providing reasonable assurance of safety and effectiveness. PMA is generally required for Class III devices that support or sustain human life, are of substantial importance in preventing impairment of human health, or present a potential unreasonable risk of illness or injury.

Frequently Asked Questions

What is Lymph node location system during sentinel biopsy procedure?

Lymph node location system during sentinel biopsy procedure is a medical device that received FDA Premarket Approval (PMA) on 2026-05-18. The listed applicant is Endomagnetics Ltd.,. The PMA number is P160053.

When did Lymph node location system during sentinel biopsy procedure receive FDA PMA approval?

Lymph node location system during sentinel biopsy procedure received FDA PMA approval on 2026-05-18, under PMA number P160053.

Who is the listed applicant for Lymph node location system during sentinel biopsy procedure?

The FDA PMA record lists Endomagnetics Ltd., as the applicant. This does not by itself establish the device manufacturer.

What is the difference between PMA and 510(k)?

PMA (Premarket Approval) is the FDA process for evaluating Class III medical devices. Unlike 510(k) clearance, which demonstrates substantial equivalence to a predicate device, PMA requires valid scientific evidence providing reasonable assurance of safety and effectiveness. PMA is the most stringent type of device marketing application required by the FDA.

What is the FDA product code for Lymph node location system during sentinel biopsy procedure?

The FDA product code for Lymph node location system during sentinel biopsy procedure is PUV.

What FDA device class is Lymph node location system during sentinel biopsy procedure?

Lymph node location system during sentinel biopsy procedure is classified as Class III by the FDA.

Related Clinical Trials

Related records are matched automatically using names, product codes, or other metadata. A match does not establish a verified clinical, scientific, corporate, or regulatory relationship; review the linked official sources.

Other records listing Endomagnetics Ltd., as applicant

Related records are matched automatically using names, product codes, or other metadata. A match does not establish a verified clinical, scientific, corporate, or regulatory relationship; review the linked official sources.

Official Source

View on FDA Database →

Data sourced from FDA Open API. For the most current and authoritative information, always refer to the official record.